Humana’s book of business is heavily Medicare Advantage and Medicare Part D, which shapes its GLP-1 coverage in a distinctive way. The Medicare Part D weight-loss exclusion limits what Humana can cover for obesity on its Medicare plans, regardless of state or specific plan benefit.<\/p>\n
Humana Part D plans in 2026 cover Wegovy\u00ae only for the cardiovascular indication, following the FDA’s March 2024 approval after the SELECT trial (Lincoff et al. 2023, NEJM) showed 20 percent reduction in major adverse cardiovascular events. Zepbound\u00ae is not covered for obesity under Part D, though some Medicare Advantage plans cover it under the OSA indication after SURMOUNT-OSA and the December 2024 FDA approval.<\/p>\n
Humana commercial plans look more like standard commercial coverage: Wegovy and Zepbound on Tier 3 with PA, depending on the employer’s benefit design. Ozempic\u00ae and Mounjaro\u00ae covered for type 2 diabetes across all plan types.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Humana’s 2026 formulary includes six GLP-1 medications: Wegovy (semaglutide for obesity and CVD), Zepbound (tirzepatide for obesity and OSA), Ozempic (semaglutide for type 2 diabetes), Mounjaro (tirzepatide for type 2 diabetes), Saxenda\u00ae (liraglutide for obesity), and Rybelsus\u00ae (oral semaglutide for type 2 diabetes).<\/strong><\/p>\n Quick Answer: Humana Medicare Part D covers Wegovy only for the cardiovascular indication (not weight loss alone)<\/p>\n Diabetes coverage is consistent across plan types. Ozempic and Mounjaro are covered for type 2 diabetes with PA on virtually every Humana plan, including Medicare Part D. The PA requires recent A1C of 7.0 or higher and prior metformin trial unless contraindicated.<\/p>\n Obesity coverage on Medicare plans is structurally limited. Part D cannot cover GLP-1s for weight loss alone. Coverage for Wegovy and Zepbound on Medicare requires the cardiovascular or OSA indications. On commercial plans, obesity coverage depends on whether the employer included weight-loss drugs in the benefit design.<\/p>\n For Humana commercial plans, the 2026 PA criteria require five elements: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity.<\/strong><\/p>\n For Humana Medicare Part D plans, the cardiovascular indication is the only viable coverage pathway. Criteria are: established CVD (prior MI, ischemic stroke, or symptomatic PAD) with ICD-10 documentation, plus BMI of 27 or higher. The 6-month lifestyle program requirement is waived under the CV pathway.<\/p>\n The cardiovascular indication has become the single most common path to Wegovy coverage on Humana plans because of the Medicare-heavy book of business.<\/p>\n For Humana commercial plans, Zepbound PA criteria mirror Wegovy, with the same BMI thresholds and 6-month program requirement.<\/strong> The SURMOUNT-1 trial (Jastreboff et al. 2022, NEJM) showed 20.9 percent weight loss at 72 weeks, which Humana reviewers cite when evaluating medical necessity.<\/p>\n Some Humana commercial plans require step therapy with Wegovy or an older agent before approving Zepbound. The step requirement can be waived with documented contraindication, intolerance, or insufficient response.<\/p>\n For the OSA indication on Medicare Advantage plans with an OSA rider, Humana’s PA requires confirmed AHI of 15 or higher on polysomnography and BMI of 30 or higher. The 6-month lifestyle program is usually waived under the OSA pathway. SURMOUNT-OSA showed AHI reduction of about 27 events per hour in the treatment arm.<\/p>\n Yes, for type 2 diabetes, across virtually all Humana plans including Medicare Part D.<\/strong> Both are on formulary in 2026, typically Tier 2 or 3 with PA.<\/p>\n The PA for Ozempic requires type 2 diabetes diagnosis with ICD-10 documentation, A1C of 7.0 or higher (or 6.5 to 6.9 with prior metformin trial), and age 18 or older. The SUSTAIN trial program (multiple Lancet and NEJM publications 2017 through 2019) is the clinical reference.<\/p>\n Mounjaro PA is similar, with the SURPASS trial program as the reference. SURPASS-2 (Frias et al. 2021, NEJM) showed A1C reductions of 2.0 to 2.3 percentage points at the highest dose, the strongest A1C lowering of any approved diabetes drug.<\/p>\n Humana does not cover off-label Ozempic or Mounjaro for weight loss. Without a type 2 diabetes diagnosis, these will be denied for obesity treatment.<\/p>\n Humana Medicare Advantage plans cover Wegovy for the cardiovascular indication only, with the same SELECT-based criteria as Part D.<\/strong> PA requires established CVD with ICD-10 documentation and BMI of 27 or higher.<\/p>\n For Zepbound, Medicare Advantage coverage depends on whether the plan includes an OSA rider. Plans with the OSA rider cover Zepbound under the SURMOUNT-OSA indication when AHI of 15 or higher and BMI of 30 or higher are documented. Plans without the rider do not cover Zepbound.<\/p>\n Ozempic and Mounjaro are covered for type 2 diabetes across all Humana MA plans, with the same PA criteria as Part D.<\/p>\n Key Takeaway: Humana commercial plans cover Wegovy and Zepbound on Tier 3 with PA when the employer benefit includes weight-loss drugs<\/p>\n Humana administers commercial employer plans through fully-insured and self-funded arrangements.<\/strong> For self-funded plans, the benefit design comes from the employer, not Humana. A self-funded employer can carve out weight-loss drugs entirely, leaving the Humana formulary intact but with a benefit exclusion.<\/p>\n The carve-out applies to obesity coverage in most cases. The cardiovascular indication for Wegovy and the OSA indication for Zepbound may be covered separately because they are not obesity-coverage line items. Check with HR or the plan document.<\/p>\n Diabetes coverage for Ozempic and Mounjaro is rarely carved out because diabetes is a near-universal benefit.<\/p>\n Pull your denial letter and find the reason code.<\/strong> The most common codes are PA-NOT-MET, NF (non-formulary), STEP-REQ (step therapy required), BMI-NOT-MET, MEDICARE-EXCL (Medicare weight-loss exclusion), and EMP-EXCL (employer carve-out).<\/p>\n For commercial PA-NOT-MET denials, file a level-1 internal appeal within 180 days. Include a Letter of Medical Necessity from your prescriber citing STEP 1 (Wilding et al. 2021, NEJM) for Wegovy or SURMOUNT-1 (Jastreboff et al. 2022, NEJM) for Zepbound.<\/p>\n For Medicare denials, you have 60 days to file a level-1 redetermination. The appeal should pivot to the cardiovascular indication (for Wegovy) or the OSA indication (for Zepbound). Document the qualifying diagnosis with ICD-10 codes.<\/p>\n For employer carve-outs on commercial plans and the Medicare weight-loss exclusion on Part D, the obesity pathway is closed. The CV and OSA indications are the only viable appeal routes for those denials.<\/p>\n For commercial plans with PA approved on Tier 3, expect a copay of $40 to $100 per month.<\/strong> High-deductible plans charge the full negotiated rate (around $900 to $1,000) until the deductible is met.<\/p>\n For Medicare Part D, the copay depends on the formulary tier and the coverage phase (initial coverage, coverage gap, or catastrophic). With the 2026 Part D out-of-pocket cap of $2,000 per year, total annual spending on a covered GLP-1 will not exceed that cap.<\/p>\n Without coverage, brand-name Wegovy lists at about $1,349 per month. The NovoCare savings card can bring eligible commercially-insured patients to $0 to $25 per month (Medicare patients are not eligible). The NovoCare Pharmacy direct cash program offers Wegovy at about $499 per month for cash-pay patients. Brand-name Zepbound lists at about $1,059 per month, with the LillyDirect direct-cash program at $349 to $499 per month for vials.<\/p>\n For commercial plans, a standard level-1 internal appeal takes 30 days, level-2 takes 30 days, and external review takes 45 days.<\/strong> Total: 4 to 5 months.<\/p>\n For Medicare Part D and Medicare Advantage, level-1 redetermination takes 7 days, MAXIMUS reconsideration takes 7 days. Most Medicare appeals are resolved within a few weeks when proper documentation is submitted.<\/p>\n Expedited appeals on both commercial and Medicare can compress timelines to 72 hours per level when prescribers attest to urgent medical need.<\/p>\n Bottom line: The SELECT cardiovascular indication and SURMOUNT-OSA OSA indication are the two paths to Medicare GLP-1 coverage<\/p>\n No. Medicare Part D structurally excludes weight-loss drugs. Wegovy is covered under Humana Part D and Medicare Advantage only for the cardiovascular indication, following the FDA’s March 2024 approval based on SELECT.<\/p>\n Ozempic is covered for type 2 diabetes, a covered Medicare benefit. Wegovy is covered for obesity, which Medicare Part D excludes by statute. The exception is the cardiovascular indication, which is a covered benefit. Same active ingredient, different FDA indications, different coverage logic.<\/p>\n No. Humana and most other insurers do not cover compounded GLP-1 medications because they are not FDA-approved finished products. Compounded semaglutide is paid out of pocket through licensed 503A pharmacies, with prescriptions written by telehealth providers like TrimRx after a clinical assessment.<\/p>\n Log into your Humana member portal and search the formulary for Wegovy. Look at the tier and check PA, step therapy, and quantity limits. Medicare plans should list the cardiovascular indication criteria specifically. If formulary search isn’t available, call the pharmacy benefit number on the back of your card.<\/p>\n Some Humana Medicare Advantage plans cover Zepbound under the OSA indication if the plan includes an OSA rider. Coverage requires AHI of 15 or higher on polysomnography and BMI of 30 or higher. Plans without the OSA rider do not cover Zepbound at all.<\/p>\n CMS data from 2023 shows roughly 38 to 41 percent of denials are overturned at level-1 internal appeal when new documentation is submitted. For Medicare denials, MAXIMUS reconsideration overturns an additional portion when CV or OSA documentation is provided.<\/p>\n For commercial plans, prediabetes alone is not a qualifying comorbidity under most Humana PA criteria. You would need BMI of 30 or higher to qualify on BMI alone, or a documented comorbidity like hypertension or dyslipidemia plus BMI of 27 or higher. For Medicare plans, only the cardiovascular indication qualifies for Wegovy coverage.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n <\/p>\n Humana’s book of business is heavily Medicare Advantage and Medicare Part D, which shapes its GLP-1 coverage in a distinctive way.<\/p>\n","protected":false},"author":11,"featured_media":92742,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Does Humana Cover GLP-1 Medications in 2026?","_yoast_wpseo_metadesc":"Humana's book of business is heavily Medicare Advantage and Medicare Part D, which shapes its GLP-1 coverage in a distinctive way.","_yoast_wpseo_focuskw":"does humana cover","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[23,29],"class_list":["post-89427","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1","tag-cost-coverage","tag-glp-1"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=89427"}],"version-history":[{"count":2,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89427\/revisions"}],"predecessor-version":[{"id":93743,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89427\/revisions\/93743"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/92742"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=89427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=89427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=89427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Is Humana’s 2026 Prior Authorization for Wegovy?<\/h2>\n
What Is Humana’s 2026 Prior Authorization for Zepbound?<\/h2>\n
Does Humana Cover Ozempic and Mounjaro?<\/h2>\n
What If I Have a Humana Medicare Advantage Plan?<\/h2>\n
What About Humana Commercial Employer Plans?<\/h2>\n
What If Humana Denies My GLP-1 Prescription?<\/h2>\n
How Much Do GLP-1 Medications Cost with Humana?<\/h2>\n
What Is the Appeal Process Timeline?<\/h2>\n
FAQ<\/h2>\n
Does Humana Cover Wegovy for Weight Loss on Medicare?<\/h3>\n
Why Does Humana Cover Ozempic but Not Wegovy on My Medicare Plan?<\/h3>\n
Does Humana Cover Compounded Semaglutide?<\/h3>\n
How Do I Check If My Humana Plan Covers Wegovy?<\/h3>\n
Does Humana Cover Zepbound for Sleep Apnea on Medicare Advantage?<\/h3>\n
What Is the Appeal Success Rate for Humana GLP-1 Denials?<\/h3>\n
Can I Get Wegovy Through Humana If I Have Prediabetes but Not Diabetes?<\/h3>\n
Related Articles<\/h2>\n
\n